top of page


PKT100 Ex vivo Data

IL1b secretion of patient monocytes at time of heart attack.

Clinical patients with heart attack- ex vivo exposure of blood to PKT100 and measurement of IL1b secretion from monocytes.

PKT100 In vivo Data

Looking at effect of PKT100 on pulmonary fibrosis, pulmonary hypertension, right ventricular remodeling and function, and survival in a model of pulmonary hypertension induced by bleomycin.

Several new small molecule compounds - the PKT 200 series, have been generated by Kassiou and Figtree, with 2021 composition of matter patent application (PCT/AU2021903786), licensed by the University of Sydney to ProKardia in exchange for 10% of the equity of Prokardia.


Recently awarded CUREator grant to develop PKT 200 molecules for the treatment of pulmonary hypertension.


Funding will be used to screen PKT200 molecules using CAD and heart attack patient-derived monocytes to establish relative efficacy versus parent compound PKT100.


The most successful of these compounds will be triaged for further preclinical efficacy and ADMET testing in relevant mouse atherosclerosis models, and potentially human trials. 

bottom of page